Pharmacy up coming FDA approve stock

``` The deep research logic is organized as follows: Okay, let's tackle this question about upcoming FDA approvals in the pharmacy sector. The user is asking for stocks related to pharmaceutical companies with FDA decisions pending in the next 30 days. First, I need to check the provided references to see what data is available. Looking at the references, Number 1 mentions Replimune Group (REPL) with an FDA review date of July 22, 2025. The drug is RP1 + Opdivo for melanoma. That's a biotech stock, but the user is asking about pharmacies. Then, Number 6 and 15 show zero results for pharmaceutical companies with pending FDA decisions in the next 30 days. That's a bit confusing because Replimune is a biotech, not a pharmacy. Maybe the user is mixing up biotech and pharma? Or perhaps they're looking for companies in the pharmaceutical sector that are about to get approvals. Wait, the user's query is "Pharmacy up coming FDA approve stock." So they might be referring to companies in the pharmaceutical industry. Let me check the references again. Number 16, 17, 18, and 19 discuss expected FDA approvals in 2025, but none of them mention specific stocks. Number 2 has an FDA calendar with several approvals, but the dates are in May and June 2025, which are already passed. The current time is July 2, 2025, so the next 30 days would be up to August 1, 2025. Looking at the FDA calendar in Number 2, the last entry is June 12, 2025, for UroGen Pharma's UGN-102. That's already passed. Number 17 mentions expected approvals in the second half of 2025, including Vertex's Journavx and Sanofi's Imaavy, but those are already approved in earlier months. Number 18 lists novel drug approvals up to May 2025, which are also past. So, based on the data, there are no pharmaceutical companies with pending FDA decisions in the next 30 days. The only relevant data is Replimune, which is a biotech, not a pharmacy. The user might be confused between biotech and pharma. Alternatively, maybe they're looking for companies that distribute pharmaceuticals, but the references don't mention any such companies. The user's profile shows they're interested in tech stocks like MAG7, meme stocks, metaverse, and robotaxis. They have a moderate risk tolerance and focus on growth. However, the current question is about pharmaceuticals and FDA approvals. Since the data doesn't support any upcoming approvals in pharma, the answer should reflect that there are no such stocks available based on the provided references. I need to structure the answer clearly, stating that there are no results found for pharmaceutical companies with pending FDA decisions in the next 30 days. Then, provide context about the biotech stock Replimune as the closest match, but clarify that it's not a pharmacy. Also, mention the broader FDA calendar for context, even though the dates are past. Make sure to cite the references properly and use the required format with tables and visualizations where applicable. ``` ### 🌟 **Conclusion** **No pharmaceutical companies** currently have pending FDA approval decisions in the next 30 days based on the provided data . However, **Replimune Group (REPL)**, a biotechnology firm, has an upcoming FDA review for its cancer drug RP1 + Opdivo (nivolumab) on **July 22, 2025** . Let’s break this down for investors. --- ### 📊 **Analysis of Upcoming FDA Catalysts** #### 1. **Pharmaceutical Sector (No Pending Approvals)** The FDA calendar for the next 30 days (July 2–August 1, 2025) shows **no pharmaceutical companies** with pending drug approvals . The closest relevant stock is **Replimune Group (REPL)**, but it operates in the biotechnology sector, not pharmaceuticals . | Stock Code | Stock Name | Last Price | Last Change | Drug Name | Indication | FDA Review Date | |------------|-------------------|------------|-------------|-------------------------|------------------|-----------------| | REPL | Replimune Group | $9.15 | -1.51% | RP1 + Opdivo (nivolumab) | Cancer, Melanoma | 2025-07-22 | #### 2. **Broader FDA Calendar Context** While no pharmaceutical stocks are pending approval, the FDA has recently approved several drugs in 2025 . For example: - **Moderna (MRNA)**: mRNA-1283 for COVID-19 (approved May 31, 2025) . - **GSK (GSK)**: Benlysta autoinjector for lupus nephritis (approved June 24, 2025) . --- ### 📊 **Key Takeaways for Investors** 1. **No Direct Catalysts in Pharma**: Investors focused on pharmaceuticals should look beyond the next 30 days for FDA-related opportunities. 2. **Biotech Plays**: If interested in FDA-driven volatility, **Replimune (REPL)** is the most relevant stock with an upcoming review . 3. **Market Context**: The FDA pipeline remains active, with recent approvals in oncology, immunology, and infectious diseases . --- ### 🌟 **Final Thoughts** For **pharmaceutical investors**, the next 30 days lack FDA catalysts. However, the broader biotech sector offers opportunities like **Replimune (REPL)** with its melanoma drug review on July 22, 2025 . Stay tuned for updates! 🚀